Manager GMP Quality
Tango Therapeutics
Manager GMP Quality
Tango Therapeutics
Develops synthetic-lethality cancer therapies
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
This role will report to the Director of Quality and operate across departments, supporting regulated activities and studies. This new role will support CMC development and clinical disposition activities for Tango’s development programs. Tango works in a matrixed, outsourced model where compliance and inspection readiness are key to our programs as we advance through the development cycle.
The Manager, Quality Assurance, will provide GMP QA oversight for Tango’s CMC development programs and clinical supply activities. This role partners cross-functionally with Technical Operations, Regulatory, and external manufacturing partners to ensure compliance with global GMP requirements while supporting the advancement of investigational therapies through clinical development.
Your Role:
What You Bring:
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Salary range 116000 - 174000 USD
Develops synthetic-lethality cancer therapies
Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.
Explore more opportunities at Tango Therapeutics